Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions Inc (NYSE:EBS)

27.13
BATS BZX Real-Time Price
As of 2:43pm ET
 +0.07 / +0.26%
Today’s Change
25.51
Today|||52-Week Range
41.91
-28.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.1B

Company Description

Emergent BioSolutions, Inc. is a biopharmaceutical company, which focuses on the research, development, and manufacture of novel vaccines and related products for prophylactic and therapeutic use against common diseases and biological weapons of mass destruction. The company operates through the Biodefense and Biosciences business segments. The Biodefense segment focuses on vaccines and antibody therapies for use against the infectious disease anthrax. The Biosciences segment engages in protein therapies to treat certain types of cancer and vaccines for use against infectious diseases. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Contact Information

Emergent BioSolutions, Inc.
400 Professional Drive
Gaithersburg Maryland 20879
P:(240) 631-3200
Investor Relations:
(301) 795-1877

Employees

Shareholders

Other institutional48.29%
Mutual fund holders45.62%
Individual stakeholders22.85%

Top Executives

Daniel J. Abdun-NabiPresident, CEO & Class III Director
Robert G. KramerCFO, Treasurer & EVP-Corporate Services
W. James JacksonChief Scientific Officer & Senior Vice President
Shauna M. TholenChief Information Officer & Senior Vice President
Adam R. HaveyExecutive VP & President-BioDefense Division